For the Quarter Ending September 2025
North America
• In the United States, the Lisinopril Price Index rose quarter-over-quarter in Q3 2025, driven by inflationary pressures.
• Lisinopril production costs increased due to a 3.0% year-over-year CPI in September 2025 and strengthening industrial electricity prices.
• Demand for Lisinopril was supported by a 5.42% year-over-year retail sales rise in September 2025 and strong pharmaceutical market sentiment.
• The Lisinopril Price Forecast indicates upward pressure from rising producer costs, with PPI up 2.6% year-over-year in August.
• Lisinopril demand outlook remains positive, bolstered by projected increases in national health spending for 2025.
• Tightening US manufacturing inventories and sluggish 0.1% year-over-year industrial production in September 2025 impacted supply.
• Primary basic organic chemical prices decreased in September 2025, offering some cost relief for Lisinopril production.
• A 4.3% unemployment rate in September 2025 and declining consumer confidence presented slight headwinds for patient affordability.
Why did the price of Lisinopril change in September 2025 in North America?
• Rising producer costs, with PPI up 2.6% year-over-year in August 2025, pressured Lisinopril prices upward.
• Strong consumer spending, retail sales up 5.42% year-over-year in September 2025, supported Lisinopril demand.
• Decreased primary basic organic chemical prices in September 2025 offered some relief to production costs.
APAC
• In China, the Lisinopril Price Index remained stable quarter-over-quarter in Q3 2025, influenced by mixed macroeconomic signals.
• Lisinopril production costs faced upward pressure in Q3 2025 due to high fine chemical production expenses.
• Lisinopril demand outlook was supported by China's expanding healthcare market during Q3 2025.
• In September 2025, the Consumer Price Index declined by 0.3%, signaling broader economic deflationary trends.
• The Producer Price Index fell by 2.3% in September 2025, indicating lower factory-gate prices for some inputs.
• China's Manufacturing Index was contracting in September 2025, impacting overall supply chain stability.
• Industrial production grew by 6.5% in September 2025, supporting a stable pharmaceutical manufacturing environment.
• Retail sales increased by 3.0% in September 2025, indirectly bolstering medication affordability and demand.
• Natural gas consumption declined in the first half of 2025, impacting production costs for some chemical inputs.
• Trade flows exhibited resilience in Q3 2025, with increased exports and port cargo throughput.
Why did the price of Lisinopril change in September 2025 in APAC?
• Deflationary pressures from a 0.3% Consumer Price Index decline in September 2025 influenced pricing power.
• High production costs in the fine chemicals market during Q3 2025 exerted upward pressure on manufacturing expenses.
• China's expanding healthcare market in Q3 2025, driven by an aging population, supported demand.
Europe
• In Germany, the Lisinopril Price Index fell quarter-over-quarter in Q3 2025, driven by weakened European chemical producer prices.
• Lisinopril production costs declined in September 2025 as producer prices fell by 1.7% year-on-year.
• Rising CPI (2.4%) in September 2025 and elevated energy costs challenged Lisinopril production expenses.
• Lisinopril demand remained sustained in 2025 due to Germany's aging population and rising chronic diseases.
• The Manufacturing Index contracted in September 2025, signaling a weaker industrial environment.
• Industrial production declined by 1.0% year-on-year in September 2025, impacting Lisinopril supply chain.
• Fragile Active Pharmaceutical Ingredient imports introduced margin pressure for Lisinopril manufacturers in 2025.
• US tariffs significantly impacted German companies' US chemical and pharmaceutical business in July 2025.
• Consumer confidence significantly deteriorated to -23.6 in September 2025, indicating broader economic pessimism.
Why did the price of Lisinopril change in September 2025 in Europe?
• Producer prices declined by 1.7% year-on-year in September 2025, reducing Lisinopril manufacturing input costs.
• The Manufacturing Index contracted in September 2025, reflecting a slowdown in overall industrial activity.
• Structurally elevated energy costs and rising electricity prices in Q3 2025 pressured Lisinopril production expenses.
For the Quarter Ending December 2022
North America
As per the data, Lisinopril prices across the United States market dropped around 3.6% during the fourth quarter of 2022 due to bearish demand from end-user pharmaceutical and healthcare industries coupled with adequate product availability among domestic retailers.
The reason behind the accumulation was that domestic merchants had excessive imports from Asia as they had placed their orders in advance. In order to increase the inquiries from the end user sector and to clear their existing stockpiles, suppliers gradually reduced their quotations. All these factors combinedly resulted in a declining price trend in the US domestic market and with prices settled at around USD 319500/MT by the end of the quarter.
Asia- Pacific
In the fourth quarter of 2022, the price trend for Lisinopril in the Asia Pacific market fluctuated. The market opened in October with bearish sentiments but enhanced in November, with prices settling at USD 297800/MT. The market supply side faced great uncertainty in the H1 of Q4, mainly due to the halt in production activities amid the Golden week holiday and Covid-19 restrictions. These factors caused an escalation in the prices of Lisinopril in November. Later, the upward trend declined in the last weeks of the quarter, with prices assembling at USD 289700/MT. Despite the ease in China's zero-COVID strategy in early December, the demand for Lisinopril was not improved throughout the month. Also, the trading activities were muted due to low inquiries from overseas buyers ahead of the year-end holidays.
Europe
During Q4 of 2022, the prices of Lisinopril resembled the trend of the Asia-Pacific region. The price of Lisinopril first decreased by 1.3% in October but later increased significantly by 2% in November, with values settling at USD 344200 /MT. In October, the lack of inquiries from the downstream pharmaceutical sector dampened the market sentiments for Lisinopril in the German domestic market. However, in the mid-quarter, the increment in Lisinopril prices was driven by low supply from Asian countries. Moreover, rising concerns about the economy and the high inflation rate in Europe impact the overall price of the product. Therefore, by the termination of Q4, the dynamics of the Lisinopril market were again suppressed as purchasing activities across the German domestic market dropped, with prices evaluated at USD 338750/MT.
For The Quarter Ending September 2022
North America
In the North American region, the Lisinopril API price trend followed an upward trajectory in the third quarter of 2022. The United States market highlighted maintaining its dominance in the area on the back of the solid downstream demand from the pharmaceutical industry. However, the insufficient product availability in the domestic market because of unstable imports from China. Since China is a significant exporter of Lisinopril, the shutdown of a few production units for maintenance caused a low output, hindered supplies, and disrupted trading activities of the products. Therefore, the prices for Lisinopril API displayed a 3.2% increment by the end of the quarter, with values assembling at USD 331500/MT in the United States.
Asia- Pacific
In the Asia Pacific region, the prices of Lisinopril API witnessed a positive sentiment in the market during the third quarter of 2022, backed by the increased downstream demand from various pharmaceutical and healthcare industries. Entering the quarter, the production rate of the Lisinopril API market was affected as China enacted a lockdown to manage the outbreak. Towards the H2 of the third quarter, the prices for Lisinopril API went higher due to the regional market supply shortage. However, after the markets reopened following the closure, the plants that manufacture Lisinopril underwent maintenance, resulting in a lack of inventories in the region. Therefore, the FOB Shanghai prices for Lisinopril API were assessed at USD 300000/MT in China at the end of the quarter with a quarterly inclination of 2.5%
Europe
With prices assembled at USD 332000/MT in July, the Lisinopril API's European market started in Q3 of 2022 on a declining note. As demand from the downstream food and pharmaceutical sector remained weak, most traders maintained a solid wait-and-see attitude. However, these values continued to improve until September and were settled at USD 341800/MT in Germany. The price rose for Lisinopril API was supported by a combination of factors, including a high demand from end users pharmaceutical, strong purchasing activity, and a lack of product availability in the German domestic market. Also, the situation in Europe worsened with ongoing lockdowns in Chinese ports and unrest in Russia and Ukraine.
For the Quarter Ending June 2022
North America
In North America, the price trend for Lisinopril API followed a downward trajectory because of weak market sentiments in the second quarter of 2022. In terms of supply, there were sufficient inventories in the market, and suppliers were able to meet demand. China's economy continued to export more goods to the United States; despite the Covid suspension, but the ongoing supply bottleneck nonetheless constrained it. But decreased demand from downstream pharmaceutical industries in regional and overseas markets negatively impacted the Lisinopril market. In this quarter, the prices of Lisinopril decreased by a total of 5.1% compared to the previous quarter, with values evaluated at USD 321000/MT in June.
Asia- Pacific
During Q2 2022, the Lisinopril API prices exhibited variation across the Asia Pacific region but remained lower than the previous quarter. With the onset of the quarter, a glimpse of beneficial market sentiments was flashed along with a 2.1% leap in price on account of increased demand in the regional market. The prices of Lisinopril API dropped drastically in May by 6.1% due to the resumption of lockdowns in significant manufacturing hubs, resulting in lower end-user demand and offtakes, which is the fundamental reason for Lisinopril's downward trend in China. As the country's major production centers remained shuttered, China's suspension and closure of factories and ports substantially impacted supply and demand projections in May. The shutdown of transportation and logistical networks affected product distribution and important international shipping ports across the country. Thus, by the quarter ending June, prices of Lisinopril API settled at USD 292500/MT in China.
Europe
During the second quarter of 2022, Lisinopril API showcased mixed sentiments in the European region due to oscillating demand fundamentals from the pharmaceutical and nutraceutical industries. The price trend of Lisinopril API fluctuated throughout the quarter with all the disruption going on across the European region. By the quarter's termination, the feeble trade market due to reduced export owing to lowering demand from the market resulted in the price declination of Lisinopril. Manufacturers were pessimist about the output, and the production level consistently fluctuated as the COVID-related restrictions in China also took a toll on both supply and demand in the domestic market. As a ripple effect in Germany, the CFR prices of Lisinopril API settled at USD 335000/MT in June.
